Search the Newsreel

Form 8K Turn Therapeutics Inc For: 12 August By Investing.com

This article announces that Turn Therapeutics Inc. has filed a Form 8K for August 12. The brief item, published by Investing.com, indicates a corporate filing for the company.

Price to earnings forward of Turn Therapeutics Inc. – NASDAQ:TTRX

TTRX|Turn Therapeutics Ord Shs|Price:8.365|Chg%:+0.115

This article provides a detailed financial overview of Turn Therapeutics Ord Shs (TTRX), including real-time quotes, key figures, market trends, and analyst ratings. The stock is trading at $8.360, with analysts giving it a "Strong Buy" rating and a target price of $16.075. The …

Turn Therapeutics (Nasdaq:TTRX) - Stock Analysis

This Simply Wall St report provides a stock analysis for Turn Therapeutics (Nasdaq:TTRX), a pharmaceutical company developing drugs for skin, nails, and eyes. The report highlights the company's financial health, volatile share price, and ongoing Phase 2 clinical trials for its GX-03 asset in …

Turn Therapeutics Inc. Revenue Breakdown – NASDAQ:TTRX

This article provides revenue breakdown information for Turn Therapeutics Inc. (NASDAQ:TTRX) within the TradingView platform. It highlights that the information is accessible under the financials section and emphasizes the various data sources and copyright information related to the financial data presented.

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing WESTLAKE VILLAGE, Calif., July 28, 2026--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder …

Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Turn Therapeutics Ord Shs (TTRX), listing major shareholders and their respective proportions. It also presents a breakdown of shareholder types, institutional holdings over recent quarters, and a table of individual shareholder activity with changes in shares held.

TTRX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Turn Therapeutics Inc. (TTRX) stock, including a 1-year price target of $26.00 by one analyst. It details the stock's recent performance, volatility, market capitalization, and upcoming earnings report. The piece also covers frequently asked questions about TTRX, offering …

Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold

Zacks Research has upgraded Turn Therapeutics (NASDAQ:TTRX) to a "Hold" rating, contributing to a diverse set of recent analyst opinions. The company, which develops pharmaceutical and medical device products using its proprietary PermaFusion platform, recently reported an earnings per share loss of ($0.03) and …

Turn Therapeutics Inc. Common Stock (NASDAQ: TTRX) Stock Price, News & Analysis

Enterprise value to revenue forward of Turn Therapeutics Inc. – NASDAQ:TTRX

This article provides financial information for Turn Therapeutics Inc. (NASDAQ: TTRX), specifically focusing on its enterprise value to revenue forward. The data is presented through TradingView, a platform offering various financial tools and market data services. It highlights key financial metrics for the company …

LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy

LADENBURG THALM/SH SH has upgraded Turn Therapeutics (NASDAQ:TTRX) to a "Strong-Buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target

Turn Therapeutics Shares Rise on Expanded Phase 2 Study For Eczema Treatment

Turn Therapeutics announced an expansion of its Phase 2 study for its eczema treatment, Lapachol, to include pediatric patients aged 2 to 11. This decision follows positive safety and efficacy data from its ongoing adult and adolescent Phase 2 study. The company believes this …

Turn Therapeutics (NASDAQ:TTRX) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen has upgraded Turn Therapeutics (NASDAQ:TTRX) to a "Hold" rating, contributing to a mixed analyst sentiment for the stock. Despite this, the company's shares are currently trading above its consensus price target of $8.00 and its 50-day and 200-day moving averages. Turn …

Turn Therapeutics (TTRX) Q4 2025 earnings summary

Turn Therapeutics (TTRX) reported its Q4 2025 earnings, highlighting significant progress in clinical trials, financial stability, and strategic partnerships during its first months as a public company. The company expects topline results for its GX-03 Phase 2 trial by mid-2026 and potential commercial revenue …

Turn Therapeutics (TTRX) Jefferies Global Healthcare Conference 2026 Summary

This article summarizes Turn Therapeutics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting the development and clinical progress of its GX-03 product. GX-03, originally for chronic wounds, has expanded indications to eczema and toenail fungus, showing strong efficacy and safety data in trials. …

Turn Therapeutics (TTRX) Corporate presentation Summary

Turn Therapeutics' corporate presentation summarizes its lead asset, GX-03, a non-systemic topical targeting inflammatory skin conditions like atopic dermatitis (AD) and onychomycosis. Clinical trials show promising results with GX-03, and the company's PermaFusion platform enhances active ingredient delivery. The company plans to use GX-03 …